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65 Miglustat therapy ameliorates bone mass and bone formation in
F508del cystic ﬁbrosis mice
C. Le Henaff1, E. Ha¨y2, F. Velard1, C. Marty2, P. Marie2, J. Jacquot1. 1University
Reims Champagne Ardenne, SFR CAP-Sante´, BIOS 4691, Reims, France;
2University Paris Diderot, Inserm U606, Paris, France
In CF patients with the F508del mutation, vertebral fractures and subsequent dorsal
kyphosis decrease pulmonary function, thus accelerating the course of the disease.
We discovered a defective CFTR-mediated Cl− channel activity and deﬁcit of
osteoprotegerin production by primary osteoblasts (the cells that form bone) of a
25-yr-old CF male (Gimenez A., 2012). Homozygous F508del-CFTR mice exhibit
a severe osteopenic phenotype (Le Henaff C., 2012). Miglustat (N butyldeoxyno-
jyrimicin) was reported to normalize CFTR-dependent chloride transport in nasal
mucosa in F508del CF mice.
We evaluated the efﬁcacy of oral miglustat treatment in restoring bone mass in
CF mice. The bone microarchitecture of CF mice, relative to wild type (WT)
littermates was evaluated after an administration of 120mg/kg/day miglustat for
28 days using in vivo micro-CT, bone histomorphometry and dynamic parameters
of bone formation. Levels of two serum growth factors, insulin-like growth factor 1
(IGF-1) and 17b-estradiol (E2) were determined.
A once-a-day oral treatment with miglustat normalized bone volume and improved
bone micro-architecture of the lumbar spine in CF mice after 4 weeks. This increase
of bone volume was accompanied to both an increased bone formation and serum
E2 level with no changes in IGF-1 level in miglustat-treated F508del mice. This
study provides ﬁrst evidence that oral administration of miglustat increases bone
mass and formation in CF mice; these ﬁndings support the therapeutic potential of
miglustat in patients with CF-related bone disease.
Supported by Association Vaincre la Mucoviscidose, France; miglustat kindly
provided by Actelion Pharmaceuticals, Switzerland.
66 Effects of a 3-year therapy with glargine among pediatric patients
with cystic ﬁbrosis and early glucose derangements
V. Fattorusso1, V. Raia1, E. Mozzillo1, C. Natale1, E. De Nitto1, N. Amato1,
F. De Gregorio1, A. Franzese1, A. Casale1. 1University of Naples, Federico II,
Pediatrics, Naples, Italy
Objectives: Diabetes and early glucose derangements adversely affect both nutri-
tional status and respiratory function of patients with cystic ﬁbrosis (CF). Aim
of this study is to evaluate the effects of a 3-years therapy with glargine among
CF-patients with early glucose derangements.
Methods: 20 CF-patients with early glucose derangements, diagnosed by means of
oral glucose tolerance test, were enrolled in this study. Parameters evaluated during
the 3-years before the beginning of insulin therapy and during the 3-years after
the beginning of therapy, were Body Mass Index (BMI) z-score, Forced Expiratory
Volume at ﬁrst second% (FEV1%) and the number/year of respiratory infections.
Mean age at the beginning of the study was 12.48 yr (range 2−19). Glargine was
administered at the mean dose of 0.23UI/kg/die (range 0.14–0.32). Mean HbA1c%
did not show signiﬁcant alterations during the treatment: 6.1% at the beginning
of the study and 6.5% at the end of the follow-up. Mean BMI z-score decreased
during the 3-years before the therapy (−0.31±0.97, −0.45±0.96, −0.55±1.14, while
showed an increase during the therapy (−0.30±1.27, −0.21±1.04, −0.40±0.94).
Mean FEV1% decreased during the 3-years before the therapy (90%, 76%, 70%),
while did not show a further decrease after the beginning of therapy (73.05%,
71.78%, 73.80%). The mean number/year of respiratory infections showed a
signiﬁcantly reduction (p< 0.05): before therapy 2.53/yr, 3.0/yr, 3.2/yr; after the
beginning of therapy 2.0/yr, 2.1/yr, 1.6/yr.
Conclusion: Glargine seems to ameliorate both nutritional status and respiratory
function of CF-patients with early glucose derangements before the onset of overt
diabetes.
67 Clinical outcomes and patient satisfaction following initiation of
the TOBI Podhaler in CF adults
C.J. Brown1, E.F. Nash1, S. Cameron1, R. Rashid1, J.L. Whitehouse1. 1West
Midlands Adult CF Centre, Heart of England NHS Foundation Trust, Birmingham,
United Kingdom
Background: In the clinical trial setting, TOBI Podhaler (TIP) has been shown to
be non-inferior to nebulised Tobramycin Inhalation Solution (TIS) in CF subjects.
There is little ‘real world’ evidence of tolerance and effectiveness of TIP.
Aim: To assess the experience of CF adults receiving TIP at our large regional UK
adult CF centre.
Methods: We report the results of a prospective observational study to evaluate
changes in lung function and quality of life of 130 CF adults who have completed
a trial of TIP. Patients also completed a visual analogue score (VAS) of satisfaction,
ease of administration and likelihood to continue (1 = positive, 10 = negative).
Results: Adverse events (AEs) were reported by 26% at trial, most commonly
cough (n = 31, 24%). Only 3 patients discontinued at trial, due to a 10% drop in
FEV1% predicted. To date 83 patients have completed 1 cycle of TIP, with median
change in FEV1% predicted of −3% (p = 0.08). 64% (n = 53) reported AEs; most
commonly cough (n = 18, 22%). 27% commenced on oral or IV antibiotics for
pulmonary exacerbation. Median VAS for satisfaction, ease of administration and
likelihood to continue were all 1/10. Quality of life in the treatment burden domain
of the CFQ-R increased by a median of 11.2 (p = 0.1). 27/130 patients to date have
discontinued TIP before completion (n = 23) or at completion (n = 4) of their 1st
cycle, 14 (52%) of whom were previously intolerant of TIS. The most common
reason for discontinuation was cough (n = 19, 27%).
Conclusion: Despite a high incidence of adverse events, patients commencing TIP
report high levels of treatment satisfaction and a trend towards perceived reduction
in treatment burden.
68 Comparison of pharmacy prescription reﬁll frequency in CF adults
before and after switching from tobramycin inhalation solution
(TIS) to TOBI Podhaler − ‘Real world’ evidence of improved
adherence
E.F. Nash1, B. Ahitan1, C.J. Brown1, K. Thakrar1, V. Carrolan1, R. Rashid1,
J.L. Whitehouse1. 1West Midlands Adult CF Centre, Heart of England NHS
Foundation Trust, Birmingham, United Kingdom
Objectives: Better adherence to inhaled tobramycin is associated with reduced risk
of pulmonary exacerbation and hospitalisation in CF individuals. TOBI Podhaler
usage is less time consuming and more convenient than tobramycin inhalation
solution (TIS) and this would be expected to improve adherence, although this
has not previously been demonstrated in the ‘real world’.
Methods: We retrospectively analysed prescription reﬁll data for all CF adults that
had been switched from TIS to TOBI Podhaler at our large UK centre from January-
October 2012. Prescription reﬁll frequency was deﬁned as the median number of
reﬁlls collected per month before and after switching medication. For all patients,
our centre was the sole supplier of TIS and TOBI Podhaler. 23 patients (10 male)
switched from TIS to TOBI Podhaler over the study period. All patients were
chronically infected with P. aeruginosa and chose to switch to TOBI Podhaler due
to expected lower treatment burden. All patients had been taking TIS for 12 months
or more before switching and the median (IQR) duration on TOBI Podhaler was
3.0 (1.5−3.6) months. Prescription reﬁll frequency signiﬁcantly increased following
switching to TOBI Podhaler (median (IQR), 0.68 (0.52–0.95) vs. 0.25 (0.04–0.42)
prescriptions/month (p = 0.04)).
Conclusion: Prescription reﬁll frequency signiﬁcantly increased in the ﬁrst few
months after switching from TIS to TOBI Podhaler, which is likely to reﬂect
improved adherence. It is yet to be determined whether this initial ﬁnding is
maintained in the longer term and whether this leads to improved clinical outcomes.
